| scholarly article | Q13442814 |
| P50 | author | Jiuchang Zhong | Q125250949 |
| Danny Guo | Q125251325 | ||
| Ratnadeep Basu | Q125251863 | ||
| Josef Penninger | Q1674391 | ||
| P2093 | author name string | Gavin Y Oudit | |
| Zamaneh Kassiri | |||
| Peter P Liu | |||
| Xiuhua Wang | |||
| James W Scholey | |||
| P433 | issue | 5 | |
| P921 | main subject | myocardial infarction | Q12152 |
| ventricular remodeling | Q7920323 | ||
| P304 | page(s) | 446-455 | |
| P577 | publication date | 2009-06-15 | |
| P1433 | published in | Circulation: Heart Failure | Q2865806 |
| P1476 | title | Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction | |
| P478 | volume | 2 |
| Q38567063 | ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension |
| Q34302600 | ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production |
| Q33939495 | ACE2 improves right ventricular function in a pressure overload model |
| Q100558878 | ACE2 mouse models: a toolbox for cardiovascular and pulmonary research |
| Q37826865 | ACE2, a promising therapeutic target for pulmonary hypertension |
| Q36929414 | ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis |
| Q38238027 | ACE2/Ang-(1-7) signaling and vascular remodeling |
| Q34866649 | ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury |
| Q47246338 | Activation pattern of ACE2/Ang-(1-7) and ACE/Ang II pathway in course of heart failure assessed by multiparametric MRI in vivo in Tgαq*44 mice. |
| Q55465043 | Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). |
| Q36727116 | Alternative Roles of STAT3 and MAPK Signaling Pathways in the MMPs Activation and Progression of Lung Injury Induced by Cigarette Smoke Exposure in ACE2 Knockout Mice |
| Q87494360 | Angiotensin (1-7) re-establishes heart cell communication previously impaired by cell swelling: implications for myocardial ischemia |
| Q91703665 | Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System |
| Q89006965 | Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology |
| Q37166953 | Angiotensin II and oxidative stress in the failing heart |
| Q42256221 | Angiotensin II downregulates ACE2-mediated enhancement of MMP-2 activity in human cardiofibroblasts |
| Q39044195 | Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. |
| Q34496676 | Angiotensin II receptors and drug discovery in cardiovascular disease |
| Q34241697 | Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling |
| Q38193206 | Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling |
| Q42554373 | Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease |
| Q37620934 | Angiotensin-converting enzyme 2 as a therapeutic target for heart failure |
| Q36829137 | Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia |
| Q35550937 | Angiotensin-converting enzyme 2: the first decade |
| Q36087047 | Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2 |
| Q33706369 | Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting |
| Q35811007 | Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats |
| Q47685507 | Blunting of cardioprotective actions of estrogen in female rodent heart linked to altered expression of cardiac tissue chymase and ACE2. |
| Q34997831 | Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice |
| Q36477635 | Cardioprotective Effects of Qishenyiqi Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin-Converting Enzyme 2 |
| Q35216408 | Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis |
| Q97429585 | Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature |
| Q98175745 | Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases |
| Q37592161 | Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems |
| Q39599579 | Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions |
| Q94597236 | Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis |
| Q92710285 | Counter-regulatory renin-angiotensin system in cardiovascular disease |
| Q97421993 | Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis |
| Q33976308 | Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction |
| Q52854048 | Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise. |
| Q38249995 | Emerging biomarkers for heart failure: an update. |
| Q53906589 | Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice. |
| Q35152116 | Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit |
| Q39073986 | Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress |
| Q38679303 | Future drug discovery in renin-angiotensin-aldosterone system intervention |
| Q51146770 | Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. |
| Q64101307 | Imbalance of angiotensin-converting enzymes affects myocardial apoptosis during cardiac arrest induced by acute pulmonary embolism in a porcine model |
| Q95828245 | Impact of sex and gender on COVID-19 outcomes in Europe |
| Q37194713 | Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. |
| Q98774280 | Is Sex a Determinant of COVID-19 Infection? Truth or Myth? |
| Q37828452 | Knocking out angiotensin II in the heart |
| Q90727949 | Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications |
| Q37310459 | Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. |
| Q37101896 | Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis |
| Q94502928 | Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure |
| Q38294134 | Myofibroblast secretome and its auto-/paracrine signaling |
| Q38064729 | Myofibroblast-mediated mechanisms of pathological remodelling of the heart |
| Q37982718 | New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis |
| Q37749836 | Novel neurohormonal insights with therapeutic potential in chronic heart failure |
| Q54517709 | Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor. |
| Q28079063 | Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells |
| Q90717662 | Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 |
| Q37862927 | Potential role of renin-angiotensin system blockade for preventing myocardial ischemia/reperfusion injury and remodeling after myocardial infarction |
| Q34046650 | Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment |
| Q37879608 | Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy |
| Q38069197 | Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system |
| Q98771893 | Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review |
| Q37884450 | Role of ACE2 in diastolic and systolic heart failure. |
| Q38170474 | Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. |
| Q34695637 | Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. |
| Q37081415 | Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure |
| Q35641067 | Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats |
| Q91730389 | Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol |
| Q42124925 | Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges. |
| Q47851502 | The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). |
| Q39745759 | The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice |
| Q93237239 | The pivotal link between ACE2 deficiency and SARS-CoV-2 infection |
| Q98947637 | The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach |
| Q27009389 | Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system |
| Q37769761 | Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters |
Search more.